Immuneering Corporation Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.68% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.68%, a 9.58% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 4.07%, a 3.56% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.93%, a 9.17% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-03-31 was 3.60%, a 166.67% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.76%, a 4.33% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.93%, a 13.58% increase from fiscal 2023.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.46%, a 156.30% increase from fiscal 2022.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.35%, a 51.69% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.68% 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 3.68% 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 3.76% 10-K · filed 2026-03-06 | |||
| 2025-09-30 | 3.76% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 4.01% 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 4.07% 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | 3.93% 10-K · filed 2026-03-06 | |||
| 2024-09-30 | 3.93% 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 3.93% 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 3.93% 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | 3.46% 10-K · filed 2025-03-20 | |||
| 2023-09-30 | 3.46% 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 3.46% 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | 3.60% 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 1.35% 10-K · filed 2024-03-01 | |||
| 2022-09-30 | 1.35% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 1.35% 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 1.35% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 0.89% 10-K · filed 2023-03-06 | |||
| 2021-09-30 | 0.89% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 1.04% 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 1.11% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 0.36% 10-K · filed 2022-03-10 | |||
| 2020-09-30 | 0.36% 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |